Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Urethra-sparing robotic prostate removal for localized prostate cancer and urinary leakage

Tests a robotic prostate operation that keeps the urethra in adults with localized prostate cancer.

Plain-language title generated from the registry record
Registry title: Total en Bloc Urethra Preservation at Robot-assisted Prostatectomy IDEAL Stage 2a

Key facts

Where
Düsseldorf and Siegen, GermanySee the 2 sites

Where in Germany

  • Clinic Bel EtageDüsseldorf, GermanyTaking people
  • Diakonie Klinikum Jung-StillingSiegen, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Sami-Ramzi Leyh-Bannurah
Trial code
NCT07678489
Record updated
1 July 2026
Original description
Prospective single-arm IDEAL stage 2a feasibility study of urethra-preserving RARP in localized prostate cancer.Read full original descriptionShow less

Total en Bloc Urethra Preservation at Robot-assisted Prostatectomy (ToP-RAP): A Prospective IDEAL Stage 2a Study

Prospective single-arm IDEAL stage 2a feasibility study of urethra-preserving RARP in localized prostate cancer.

Inclusion: Life expectancy >=10 years (biological age); No prior prostate therapy (laser enucleation, TURP, focal therapy); No pelvic/prostate radiotherapy; No prior abdominal/rectal surgery; No prior (neoadjuvant) androgen-deprivation therapy; No prior stroke/cerebral ischemia with neurological sequelae; No neurological disease (e.g., Parkinson's); Transrectal or transperineal bilateral biopsy >=12 cores (MRI-ultrasound fusion, targeted + systematic); PSA <=15 ng/mL; prostate volume <=80 mL; Biopsy ISUP grade 1-3 (= Gleason 3+3 / 3+4 / 4+3); No Gleason pattern 5; no intraductal, cribriform or neuroendocrine carcinoma; mp/bpMRI (mandatory if biopsy Gleason >=3+4); No suspected metastases at staging.

Exclusion: Failure to meet any inclusion criterion, or patient declining ToP-RAP (offered standard RARP per EAU guidelines).

ClinicalTrials.gov NCT07678489